Diane Hollenbaugh

Diane Hollenbaugh has over 30 years of experience in the biopharmaceutical industry. Diane is currently the CSO at Bonum Therapeutics since September 2022. Prior to this, they held the role of CSO at Good Therapeutics, Inc. from August 2021 to September 2022. Diane also served as the Head of Research at Good Therapeutics, Inc. from May 2019 to August 2021.

Before joining Good Therapeutics, Inc., Diane held the position of Executive Director, Immuno-Oncology Discovery at AbbVie Biotherapeutics from September 2013 to April 2019. Diane was the Senior Director of Antibody Discovery at Igenica from June 2012 to September 2013.

Diane also has experience in biotech consulting, having worked at DH Biopharma Consulting from January 2011 to June 2012. Prior to that, they served as the Senior Director of Antibody Technology and Oncology at Merck Research Laboratories, Schering-Plough Biopharma, and FivePrime.

Diane's career in the biopharmaceutical industry began at Bristol-Myers Squibb, where they worked in Immunology/Inflammation from April 1991 to February 2002.

Diane Hollenbaugh holds a Ph.D. degree in the Division of Chemistry and Chemical Engineering from Caltech. Diane earned their B.S. in Chemistry from the University of Washington. No specific start or end dates are provided for either of their educational programs.